Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Report Date: April 17, 2026
Principal Executive Office: Marseille, France
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated April 17, 2026, into the company's registration statements on Form F-3 and Form S-8. The document serves as a formal notification of the press release content to the SEC.
Key Financial Metrics
The provided filing text does not contain specific financial data. It is a cover document referencing an external press release. Consequently, the following metrics are not available in this text:
- Revenue: Not provided.
- Profit/Loss: Not provided.
- Cash Flow: Not provided.
- Margins: Not provided.
- Debt and Liquidity: Not provided.
Material Changes
The filing text does not disclose specific material changes in financial performance or operations. It only indicates that a press release was issued on the report date, the content of which is incorporated by reference but not detailed in the provided text.
Guidance, Outlook, and Risks
Management Commentary: The text notes the exclusion of a specific quotation from Sonia Quaratino, Chief Medical Officer, from the incorporation by reference, though the full press release content is not included here.
Guidance and Outlook: No forward-looking guidance or outlook is present in the provided text.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated April 17, 2026) to obtain the actual news, clinical data, or corporate updates referenced in this filing.
- Verify the specific content of the excluded quotation from the Chief Medical Officer if relevant to clinical trial interpretations.
- Check the referenced registration statements (Form F-3 File No. 333-276164 and Form S-8 File No. 333-282031) for how this press release impacts ongoing capital raising efforts.
- Confirm if the press release contains material non-public information regarding clinical trial results or regulatory approvals, as this is the primary purpose of a Form 6-K.